Scandinavian ChemoTech
Scandinavian ChemoTech AB is a Swedish medical technology company based in Lund that develops tumor-specific electroporation (TSE™) systems for cancer treatment in humans and animals. Its business centers on patented treatment platforms, associated treatment kits, and clinical applications sold through the Human Care and Animal Care segments, with activity focused mainly in Sweden, India, Europe, and North America.
Fiscal year 2025 · change from previous year
Development 2021–2025
Business
Share of revenueConsumable treatment kits and related veterinary oncology products used in animal cancer care.
Human cancer treatment solutions and associated clinical applications, primarily for India.
Clinical studies, collaborations, and evidence generation supporting product adoption.
Product registration and commercialization support for new markets.
Customers
The company sells to veterinary clinics, animal hospitals, and distributors serving animal oncology markets, especially for equine and companion-animal use. It also targets human-care buyers and channel partners in India where cost-effective cancer treatment options are needed. In practice, demand is driven by clinicians and distributors seeking a differentiated, lower-dose treatment platform with clinical validation and regulatory clearance.
Buy Animal Care treatment kits for oncology procedures in companion animals and horses.
Purchase and resell products into regional markets, especially where direct sales coverage is limited.
Collaborate on studies, validation, and product refinement to support adoption and registration.
Buy or evaluate human oncology solutions where affordable treatment alternatives are scarce.
Strategy
The company’s strategy is to commercialize its patented TSE™ platform through focused segment execution: Animal Care for near-term sales and Human Care for longer-term market development. It is also building adoption through clinical evidence, university partnerships, and regulatory registrations that expand the addressable market. Distributor-led commercialization and product validation are central to scaling without a large direct-sales footprint.
Animal Care is the main revenue engine and benefits from short order-to-delivery cycles and repeat kit demand.
India offers a large need for cost-effective oncology solutions and could broaden the company’s addressable market.
Clinical validation supports physician and veterinarian adoption and helps differentiate the platform.
Regulatory approvals are required before sales can scale in new countries.
Geography
ChemoTech is headquartered in Lund, Sweden, and its business is organized around Nordic development and international commercialization. The company’s Human Care focus is primarily India, while Animal Care is concentrated in Scandinavia, Europe, and North America. Geography matters because regulatory pathways, distributor coverage, and clinical adoption differ materially across these markets.
Risks
ChemoTech depends on specialized expertise, external distributors, and continued product validation, so execution risk is tied to both commercialization and clinical adoption. The business also faces regulatory, financing, intellectual property, and competitive risks typical of early-stage medtech companies. Because sales are concentrated in niche oncology applications and multiple geographies, delays in approvals or slower-than-expected uptake can materially affect results.
- Regulatory approval delaysImpact: HighLikelihood: High
Products must be registered country by country before commercialization can scale.
Exposure: India and other target markets
- Financing riskImpact: HighLikelihood: High
Expansion, product development, and market entry require capital before cash generation is broad-based.
Exposure: Growth funding
- Dependence on specialized expertiseImpact: HighLikelihood: Medium
The company develops technically advanced medical products that require scarce scientific and commercial skills.
Exposure - Distributor and agent dependenceImpact: High
External sales channels are central to market access, so partner performance directly affects revenue.
Exposure: International sales execution
- Intellectual property protectionImpact: MediumLikelihood: Low
The TSE™ platform relies on patents and proprietary know-how that competitors could attempt to copy.
Exposure: Technology differentiation
- Competition from better-capitalized medtech firmsImpact: Medium
Larger competitors could outspend the company on development, distribution, and regulatory work.
Exposure: Niche oncology devices
Accounting
Judgemental itemsSales are often delivered by period-end, so shipment and acceptance timing can shift reported revenue between quarters.
Impact: Quarterly comparability
Product development and registration efforts may be capitalized and later tested for impairment.
Impact: Balance sheet and earnings
Receivables and short order cycles affect cash conversion and reported operating performance.
Impact: Cash flow and liquidity
A limited number of orders can cause large swings in quarterly revenue and margins.
Impact: Period-to-period comparability
Similar listed companies
Publicly listed companies with a comparable business focus.
Active Biotech
ACTI · Health Care
Active Biotech AB is a biotechnology company focused on developing first-in-class immunomodulatory treatments for oncology and immunology indications.
BioNTech SE
BNTX · Biological Products, (No Diagnostic Substances)
BioNTech SE is a biotechnology company focused on discovering and developing immunotherapies and other medicines, with a major commercial base in COVID-19 vaccines and a growing oncology pipeline.
Elekta B
EKTA-B · Health Care
Elekta is a global leader in radiotherapy solutions, specializing in advanced technologies to treat cancer and neurological diseases.
Cavotec Group
CCC · Industrials
Cavotec Group AB is an engineering company specializing in connection and electrification solutions aimed at decarbonizing ports and industrial applications globally.
Essity A
ESSITY-B · Consumer Staples
Essity Aktiebolag is a global hygiene and health company headquartered in Sweden.
CellaVision
CEVI · Health Care
CellaVision is a global medical technology company specializing in the development and sale of advanced solutions for the routine analysis of blood and other body fluids.
Last updated: 24/09/2026